Most people think aging is inevitable, like the weather. We used to think that too, until it became clear that aging is driven by biology that we can now understand, measure, and begin to control.
Today, we’re sharing why we started HexemBio, what we’re building, and why this moment feels different from the decades of longevity science that came before it.
Read More – Noon Raises $44M in Seed Funding
The dominant framing in aging research goes something like this: cells accumulate damage over time, epigenetic programs drift, tissue function declines. Intervene at any number of points, clear senescent cells, reset methylation patterns, inhibit mTOR, and you might slow the process.
This framing isn’t wrong, but we now know there is another less-conventional path to resist aging .
When you trace where most of the inflammation driving systemic aging originates, you keep arriving at the same place: the blood. Specifically, the hematopoietic stem cells (HSCs) in the bone marrow, the cells responsible for producing every blood and immune cell in your body. Not just red blood cells, but white blood cells, platelets, and the full immune repertoire: T cells, B cells, myeloid cells – the infrastructure that keeps infection, cancer, and inflammation in check.
As HSCs age, they change character. Research published across multiple labs has shown they shift output toward myeloid cells at the expense of lymphoid cells, weakening adaptive immunity. They accumulate mutations through clonal hematopoiesis. They produce chronic low-grade inflammation, what researchers call “inflammaging,” that circulates system-wide.
That signal reaches the brain, the skin, the organs. It doesn’t stay in the blood.
The connection between HSC aging and systemic decline has been documented across multiple model systems. Heterochronic parabiosis experiments showed this decades ago: young blood helps old tissue, and old blood hurts young tissue.
Whatever the precise mechanism, the signal originates in the blood system, and the blood system is where we believe intervention must begin.
And today, there is no approved therapy that directly addresses this. You can manage the downstream consequences: treat the infection, transfuse the blood, suppress the inflammation. But reversing the dysfunction in the stem cells themselves? Nobody had a real approach until now.
Read More – Stipple Bio Raises $100M in Series A Financing
